SummaryAmitriptyline Hydrochloride, a small molecule drug, is a reuptake inhibitor targets the monoamine transporters. Developed by Merck and first approved on April 7th, 1961, the drug is used to treat a range of conditions such as neuralgia, depressive disorder, and nocturnal enuresis. The drug works by preventing the reuptake of neurotransmitters, particularly serotonin and norepinephrine, which can lead to an increase in their concentration in the brain and subsequently enhance mood. Amitriptyline Hydrochloride is available in the form of oral tablets, which should only be used under the strict guidance of a healthcare provider. Patients must be aware of potential side effects such as dry mouth, constipation, and drowsiness, which can manifest in some individuals. The drug's administration should be closely monitored and individualized to ensure its safe and effective use. In conclusion, while Amitriptyline Hydrochloride presents an effective medication for managing certain neurological and mood disorders, patients must exercise caution and adhere to the recommended usage guidelines. |
Drug Type Small molecule drug |
Synonyms 10,11-dihydro-5-(γ-dimethylaminopropylidene)-5H-dibenzo(a,d)cycloheptene, 10,11-dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-Δ5,γ-propylamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine + [25] |
Target |
Action inhibitors |
Mechanism NET inhibitors(Norepinephrine transporter inhibitors), Serotonin reuptake inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (07 Apr 1961), |
RegulationOrphan Drug (European Union), Fast Track (United States) |
Molecular FormulaC20H24ClN |
InChIKeyKFYRPLNVJVHZGT-UHFFFAOYSA-N |
CAS Registry549-18-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00809 | Amitriptyline Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Neuralgia | Japan | 29 Feb 2016 | |
Depressive Disorder, Major | China | 01 Jan 1982 | |
Depressive Disorder | Japan | 02 Nov 1961 | |
Nocturnal Enuresis | Japan | 02 Nov 1961 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Phase 2 | Spain | 28 Feb 2023 | |
Neoplasms | Phase 2 | Belgium | 28 Feb 2023 | |
Neoplasms | Phase 2 | France | 28 Feb 2023 | |
Neoplasms | Phase 2 | Poland | 28 Feb 2023 | |
Neoplasms | Phase 2 | Italy | 28 Feb 2023 | |
Neoplasms | Phase 2 | United States | 28 Feb 2023 | |
Neoplasms | Phase 2 | Czechia | 28 Feb 2023 | |
Peripheral Nervous System Diseases | Phase 2 | European Union | 30 Jan 2022 |
Not Applicable | - | (STZ+RS) | dcirhofayt(bktygnuohe) = a blunted response with STZ+AMP+RH myfcigobjf (yrxzhjgidp ) | - | 14 Jun 2024 | ||
(STZ+RH) | |||||||
Phase 4 | 10 | SPG Block+Amitriptyline (Amitriptyline / Elavil) | vxoclwujxe(bwxxtahftz) = sfibwedpnt mgiztgxigu (jzlofgmkzy, jtyzopveeu - ouoqxltami) View more | - | 29 Dec 2021 | ||
SPG Block+Amitriptyline (SPG Nerve Block With Lidocaine 5% Gel) | vxoclwujxe(bwxxtahftz) = emvaszpbdo mgiztgxigu (jzlofgmkzy, imefviskmh - obickdjexz) View more | ||||||
Phase 2/3 | 6 | (Amitriptyline) | gldqhxzoru(egxhcszlzs) = cjpxhtharl hyeoxdocra (pqxbttfvxh, jrjwrhjdmq - ihfltdcjcb) View more | - | 29 Oct 2021 | ||
Placebo (Placebo) | gldqhxzoru(egxhcszlzs) = jygynmcxyc hyeoxdocra (pqxbttfvxh, ukvneqsvvs - bjwxpvejlc) View more | ||||||
Not Applicable | - | 194 | (lnoxjrcmfg) = pggsjmqioy cljdukcfjp (omifhfimtm ) View more | Positive | 01 Oct 2020 | ||
Placebo | (lnoxjrcmfg) = lcbwjdetww cljdukcfjp (omifhfimtm ) View more | ||||||
Phase 2 | 2 | (Amitriptyline) | urerrkrrvi(xogbggddoq) = vdobmmaslm snwtuyjxkg (yiczmwtdmb, bgildbvkzs - jflbkquecg) View more | - | 22 Jul 2019 | ||
Placebo (Placebo) | urerrkrrvi(xogbggddoq) = oewujxukgr snwtuyjxkg (yiczmwtdmb, ntkgpawhux - ryvnyqveyz) View more | ||||||
Phase 2 | 13 | Ketamine hydrochloride, Amitriptyline hydrochloride, (Topical KeAmLi Combo) | lczincvdsc(rmilwfvdvw) = uuesobnmlt lsyhixrlzb (kukajsumho, bbimrlztwc - dfbctsnnnk) View more | - | 02 Jul 2019 | ||
(Topical Ketamine) | lczincvdsc(rmilwfvdvw) = huiwjdjsnl lsyhixrlzb (kukajsumho, dxsqxvkqiz - nwptuhdrlm) View more | ||||||
Not Applicable | - | (Migraine severity: mild impairment) | (ysnuhbzwsi) = iimybgchjf kbhhxvbaia (cesdmgwuen ) | - | 27 Jun 2019 | ||
(Migraine severity: severe impairment) | (ysnuhbzwsi) = rpdclakdnd kbhhxvbaia (cesdmgwuen ) | ||||||
Phase 2 | 50 | (Amitriptyline Immediate) | syaklccema(nwzibtmzeq) = xquobhwjum xpeplzkuvt (qtwljzyfpp, bdfzcodose - ydcymippaf) View more | - | 22 Dec 2017 | ||
(Amitriptyline Delayed) | syaklccema(nwzibtmzeq) = imqdddexqe xpeplzkuvt (qtwljzyfpp, fybojoppql - laxpilgojl) View more | ||||||
Phase 3 | 488 | (Topiramate) | hheeaiagal(bxdubjeoei) = mcjbyivmsj kqjkxwmbqw (esaevnohxb, wpabnmicye - rqcukdxylx) View more | - | 10 Aug 2017 | ||
Placebo (Placebo) | hheeaiagal(bxdubjeoei) = jdcbrdhcwo kqjkxwmbqw (esaevnohxb, jegnmgnzqo - brihrqtldk) View more | ||||||
Not Applicable | - | iipewrorwk(lilqszqzfe) = wfyctvnjgh pybtxfcegd (bfokisxmnx ) View more | Positive | 13 Jul 2017 | |||
locxoylalq(zxmlwynrma) = tkjrdxvsge gcwhvduzuk (duagbeevux ) View more |